<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064764</url>
  </required_header>
  <id_info>
    <org_study_id>Symplicity AF</org_study_id>
    <nct_id>NCT02064764</nct_id>
  </id_info>
  <brief_title>Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation</brief_title>
  <acronym>Symplicity AF</acronym>
  <official_title>Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the feasibility of performing both renal&#xD;
      nerve denervation and pulmonary vein isolation on the same patient with the intent of&#xD;
      characterizing both safety and effectiveness in a paroxysmal and persistent atrial&#xD;
      fibrillation population with hypertension. To assess safety, the study will measure the&#xD;
      occurrence of a composite safety endpoint and, to assess effectiveness, the study will&#xD;
      measure freedom of chronic treatment failure through a minimum of six months of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety composite events</measure>
    <time_frame>Up to one or six months post procedure depending on the event</time_frame>
    <description>The objective characterizes the rate of safety composite events, adjudicated as a serious adverse event, within each of the two study arms and also characterizes the difference in the rates between study arms. Each event in the composite has its own time frame, either one month or six months post procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of chronic treatment success between study arms</measure>
    <time_frame>Minimum of six months</time_frame>
    <description>Chronic treatment success is freedom from chronic treatment failure. Chronic treatment failure is defined as the occurrence of either a documented episode of AF lasting 30 seconds or longer or an intervention for AF.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Cryoablation only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoablation and renal nerve denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary vein isolation plus renal nerve denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal nerve denervation</intervention_name>
    <arm_group_label>Cryoablation and renal nerve denervation</arm_group_label>
    <other_name>Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <arm_group_label>Cryoablation and renal nerve denervation</arm_group_label>
    <arm_group_label>Cryoablation only</arm_group_label>
    <other_name>Arctic Front Advance™ Cardiac Cryoablation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Drug refractory recurrent symptomatic paroxysmal or persistent atrial fibrillation&#xD;
&#xD;
          -  Office-based systolic blood pressure of ≥140 mm Hg based despite treatment with 1 or&#xD;
             more antihypertensive medications&#xD;
&#xD;
          -  Age 18 years to 80 years old.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Renal artery anatomy that is ineligible for treatment including: Lacks at least one&#xD;
             renal artery for each kidney with ≥3 mm diameter and minimum treatable length per the&#xD;
             Spyral Instructions for Use, Renal artery stenosis (&gt;50%) or renal artery aneurysm in&#xD;
             either renal artery, A history of prior renal artery intervention including balloon&#xD;
             angioplasty or stenting, Renal artery which contain calcification which does not allow&#xD;
             at least four radio frequency ablations to be delivered , Diffuse fibromuscular&#xD;
             dysplasia (FMD) or FMD which does not allow at least four radio frequency ablations to&#xD;
             be delivered; FMD defined as visible beading of the artery on angiography , Unilateral&#xD;
             kidney.&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate of &lt;30 mL/min/1.73m2.&#xD;
&#xD;
          -  Pregnant, nursing or planning to be pregnant. (Female participants of childbearing&#xD;
             potential must have a negative serum or urine human chorionic gonadotropin (hCG)&#xD;
             pregnancy test prior to angiography).&#xD;
&#xD;
          -  Currently enrolled or plans to participate in a potentially confounding drug or device&#xD;
             trial during the course of this study. Co-enrollment in concurrent studies is allowed&#xD;
             when documented pre-approval is obtained from the Medtronic study manager.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Chinitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Medical Group-Cardiology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPHS-Marquette</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Cherry Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-5711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

